Vifor Pharma Revenue and Competitors

Basking Ridge, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vifor Pharma's estimated annual revenue is currently $527.8M per year.(i)
  • Vifor Pharma's estimated revenue per employee is $201,000

Employee Data

  • Vifor Pharma has 2626 Employees.(i)
  • Vifor Pharma grew their employee count by 3% last year.

Vifor Pharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head IT Technology ServicesReveal Email/Phone
3
Head Commercial Training & CapabilitiesReveal Email/Phone
4
Regulatory Affairs Director for Latin AmericaReveal Email/Phone
5
Customer ManagerReveal Email/Phone
6
Country Manager Assistant NetherlandsReveal Email/Phone
7
Nordic Omnichannel ManagerReveal Email/Phone
8
Manager Acess MarketReveal Email/Phone
9
Launch & Project ManagerReveal Email/Phone
10
Territory Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Vifor Pharma?

Pharmaceutical Products, Iron Deficiency, Nephrology, Prescription Medicines, Consumer Healthcare Switzerland, Vifor Fresenius Medical Care Renal Pharma, Infectious Diseases / OTX, OM Pharma Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. The company operates four franchises: Iron; Vifor Fresenius Medical Care Renal Pharma; Infectious Diseases/OTX; and Consumer Healthcare Switzerland. Vifor Pharma has manufacturing sites in Switzerland, the UK, and Portugal. For more information about Vifor Pharma and its parent company Galenica, please visit www.viforpharma.com and www.galenica.com. Vifor Pharma has set up this community to share with you news about the company and the current open positions. Sensitive topics, such as discussions about products or treatment options should be addressed privately with your physician. If you are concerned with an adverse event of a drug or a complaint regarding a product, please directly email safety@viforpharma.com or call +41 79 788 03 09. Political and religious discussions are not allowed on this site, as well as inflammatory, defamatory and racist comments. If it is believed that the end result of a discussion will be political, religious or contains inappropriate statements the post may be removed.

keywords:N/A

N/A

Total Funding

2626

Number of Employees

$527.8M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vifor Pharma News

2022-04-13 - Vifor Pharma AG (OTCMKTS:GNHAF) Short Interest Update

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in...

2022-03-30 - American Kidney Fund Announces Support from Vifor Pharma ...

ROCKVILLE, Md., March 31, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced sponsorship from Vifor Pharma for an...

2022-03-22 - Publication of definitive end result for Vifor Pharma tender offer

CSL re-affirmed its intention to have Vifor Pharma submit an application to SIX Exchange Regulation for the de-listing of its shares in...

2021-11-26 - Vifor Pharma Acquires Sanifit Therapeutics

Vifor Pharma, a St. Gallen, Switzerland-based is to acquire Sanifit Therapeutics, a Palma, Spain-based clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders. Under the terms of the acqu ...

2021-11-26 - Vifor Pharma Acquires Inositec

Vifor Pharma, a St. Gallen, Switzerland-based is to acquire Inositec AG, a Zurich Switzerland-based developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the shares ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1119.3M35220%N/A
#2
$998.6M49688%N/A
#3
$1500M5355-6%N/A
#4
$1434.5M71373%N/A
#5
$1710.5M8426N/AN/A